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Abstract
Amphetamines are frequently prescribed to young children for attention deficit hyperactivity
disorder (ADHD). Due to the recent rise in ADHD diagnoses and the resulting increase in
amphetamine intake in children, we investigated how amphetamine exposure impacts the
development of stereotyped behaviors and the neural circuit that governs these behaviors. The
zebrafish (Danio rerio) was used as our model organism because of the extensively studied
developmental milestones these fish provide. Using escape responses as a behavior model, we
exposed embryos to three doses of amphetamine (10 μg/ml, 20 μg/ml, and 30 μg/ml)
environmentally during the first 48 hours of development and used high-speed videography to
identify escape behavior deficits at two time points. All doses of amphetamine exposed embryos
took significantly longer to complete escape behaviors compared to controls at both time points
and also displayed an increase in spastic behaviors. Also, amphetamine treated fish took
significantly longer to emerge from their surrounding chorions compared to controls, which
suggests developmental delays. Amphetamine fish exhibited morphological abnormalities that
included tail underdevelopment, lordosis, and significantly shorter body lengths. Underlying
interneural deficits are further supported with fluorescent antibody staining in the spinal cord,
where inhibitory expression was significantly higher in the high amphetamine dose compared to
controls. This study using 24 and 48 hpf zebrafish offers a novel perspective on early
amphetamine exposure during peak developmental times. Furthermore, the combination of
delayed stereotyped behaviors and morphological irregularities in this study helps provide
insight to the existing literature on development and early amphetamine exposure.

Introduction:
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Attention deficit hyperactivity disorder (ADHD) is an early onset neurobehavioral disorder that is
characterized by academic underachievement, fidgeting, impulsiveness, and disorganization
(Loe & Feldman, 2007). Prevalence of ADHD is also on the rise and it is estimated that 5
percent to 9% of the population suffer from ADHD alone, making this the most common
behavior disorder seen today in children and adults (Chavez, Sopko, Erhet, Paulino, &
Goldberg, 2009). From 2001 to 2011, the diagnosis of ADHD increased 24% (Greenhill, Pliszka,
& Dulcan, 2002). The etiology of ADHD is unknown but current genetic and heritability research
suggests that alterations of genetic combined with environmental factors are to blame (Chavez
et al., 2009), making this a complex disorder.
There is an entire suite of treatment options available for those with ADHD. Although, nonpharmacological treatments exist, the most common treatments used are stimulant
(methylphenidate, dexmethylphenidate, and mixed amphetamine salts) and non-stimulant
(atomoxetine, clonidine, and guanfacine) pharmaceuticals (Antshel et. al., 2011).
Amphetamines are the most common pharmaceutical treatment for ADHD in children and adults
and work by effectively stimulating the central nervous system in humans and other vertebrates.
Numerous studies have revealed that amphetamines can have advantageous results in people
with attention disorders (Berman, Kuczenski, McCraken, & London, 2009) and have been
shown to increase concentration, focus, and alertness in these individuals. Even though positive
behavioral and mental alterations have been seen with amphetamines, there are several
negative side effects possible when taking these drugs including dizziness, anxiety/fear, loss of
appetite, insomnia, and headaches (National Toxicology P., 2005). In extreme cases, stimulantinduced psychosis has been reported (Berman et al., 2009).
The use of amphetamines has been on the rise during the past two decades (Berman et al.,
2009). The Drug Enforcement Agency estimates over 8 million prescriptions were written for
amphetamines in 2000, reflecting a 1600% increase in amphetamine prescriptions over the
previous nine years (Drug Enforcement Administration, 2004). The rise in diagnoses for ADHD
could be partially responsible for such a dramatic escalation of amphetamine prescriptions. Due
to the rise of amphetamine exposure within the population, it is becoming increasingly important
that we better understand how these drugs influence the body and long-term exposure
implications.
Amphetamines are FDA-approved and are classified under the Convention on Psychotropic
Substances as Schedule II, which indicates a prescribed medical use and strict monitoring due
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to the potential for abuse and severe psychotropic effects (National Toxicology P., 2005). The
wide range of doses generally prescribed starts at 2.5 mg tablets daily, usually in young children
aged 3 - 6, 5 - 40 mg/day for children ages 6 – 12, and up to 60 mg daily for adults (National
Toxicology P., 2005). Once ingested, amphetamines stimulate the central nervous system by
increasing the availability of several neurotransmitters, mainly dopamine, norepinephrine, and
serotonin, within the axonal synaptic gaps (Berman et al., 2009). Furthermore, psychostimulants
like amphetamines alter reward systems and cause addiction and dependence (Cadet, 2009)
most likely due to the association of these neurotransmitters (dopamine and norephineprine)
with reward-motivated behavior in the brain. According to a 1971 survey, amphetamines were
found to be consumed and abused by up to 30% college students without a prescription
(Executive Board AAoP, 1973). In a more current 2006 US National Study, it was discovered
that amphetamines are the most abused prescription medication and second only to marijuana
in illicit drug use (Berman, O'Neill, Fears, Bartzokis, & London, 2008), making additional
research on these drugs all the more necessary.
Despite the prevalence and significance of amphetamine abuse, there is a surprising lack of
research has been done on how chronic, low-doses of amphetamine influence a developing
brain. A majority of existing amphetamine research focuses on high-level doses and addiction.
Although it is not known to be neurotoxic at low, long-term therapeutic dosages, amphetamines
are neurotoxic at high concentrations with short exposure times (Berman et al., 2009). In
addition, since the enteric-coated time-release amphetamine capsules became available in the
1990’s, prescribed individuals maintain a constant exposure to these drugs (Berman et al.,
2009). A 2005 study looked at amphetamine neurotoxic potential and the resulting damages on
dopaminergenic nerve endings in non-human primates (Ricuarte et al., 2005). Baboons and
squirrel monkeys, were treated human relevant doses of mixed amphetamine salts for 4 weeks
and plasma concentration results reflected those of children treated clinically in a similar study
(McGough et al., 2003). The researchers also found significant reductions in striatal dopamine
concentrations and dopaminerginic neurotoxic changes influenced by amphetamine. This study
shows that amphetamines can negatively influence dopaminergic regions of the brain with
human relevant doses, however, more information is needed for lower daily therapeutic doses
mimicking a child’s exposure during early development.
Little is known about the effects of amphetamine on the still-developing brain, bodies, and
neurological pathways of the youth and adolescents taking these psychostimulants. Currently,
amphetamine prescription is approved for children as young as 3 years old by the U.S. Food
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and Drug Administration (Berman et al., 2009). Amphetamine exposure in children can occur
from methods other than direct ingestion. For example, amphetamines have been shown to be
present in breast milk for up to 24 hours past ingestion when consumed by the breast-feeding
mother (Bartu Bartu, Dusci, & Llett, 2008). Fetuses can also be exposed to amphetamine inutero (Tan, 2003). Women of childbearing age will often continue to take amphetamine while
pregnant because of the desired effects of attentiveness and appetite suppression when taking
amphetamines. Recently, the National Toxicology Program (NTP) and the Center for the
Evaluation of Risks to Human Reproduction (CERHR) evaluated possible adverse effects of
amphetamines on developmental health. They concluded that there is some concern for
potential neurobehavioral alterations in humans when exposed prenatally; however, data was
deemed insufficient on studies related to growth and other developmental effects for human and
animal studies (National Toxicology P., 2005).
Some studies suggest that amphetamine exposure results in lower body weights with exposure
both in-utero, and at a young age. A 1996 Swedish study (Cernerud, Eriksson, Jonsson,
Steneroth, & Zetterstrom, 1996) followed 65 children for 14 years born to women who abused
amphetamine during pregnancy. Females were significantly shorter and lighter than their peers
at 10 years of age compared to the amphetamine-exposed males who were heavier and taller
than peers at 14 years of age. In addition, children exposed to amphetamine in-utero had
significantly lower academic scores compared to peers. Additionally, in a 2003 experiment,
pregnant rats were injected with low (5 mg/kg/day) and high (10 mg/kg/day) doses of
amphetamine for 15 days (Tan, 2003). There was a significant difference in the birth weights
between the control and amphetamine treatment groups and their weights continued to be
different until 22 and 60 days after birth. Another example of lower body weights possibly
influenced by amphetamines is in a 2010 experiment, where rat pups were administered a wide
range of d-amphetamine with and without milk formula via intragastric intubation for five days. It
was shown that postnatal amphetamine exposure resulted in dose-dependent lower body
weights paired with a reduction in somatic growth (Smith & Chen, 2010). Alternately, some
literature reflects little to no effects caused by amphetamine exposure. A 2012 study
administered amphetamines to adolescent rhesus monkeys twice daily for a total of 18 months.
After treatment, the researchers found repeated exposure to amphetamine resulted in normal
growth rates, activity, cognitive function and dopamine transporter values (Soto et al., 2012).
The conflicting results from numerous studies regarding the effects of amphetamines on the
developing brain emphasizes the need for additional research on this subject.
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Animal Model
The zebrafish (Danio rerio) was used in this study to investigate the effects of amphetamine
exposure on development. The zebrafish is a tropical freshwater actinopterygii that has been
used increasingly as a model species in neuroscience research over the past decade. These
extensively studied fish are considered suitable models for developmental and genetic analysis
because developmental milestones can be predicted to the nearest hour and developing fish will
display stereotyped behaviors during their rapid growth period. Additionally, previous genetic
screenings of the zebrafish enables easy translation of genetic work from zebrafish to human
developmental genes. Along with predictable behaviors, internal structures of the larval fish are
visible, making morphological, physiological, and behavioral assays straightforward and
allowing in vivo visualization (Ganser & Dallman, 2009). Hundreds of embryos are often
produced by a single mating of 6 to 10 fish, which allows for large treatments groups and largescale screenings (Neuhauss, 2003). Zebrafish maintenance and husbandry is also economically
advantageous when compared to a higher-level model. The list for similarities between
zebrafish and human is long and includes diet (omnivorous), determinate growth, diploid
genome structure, similar organ structure, and multiple similarities in their molecular biology
(Lieschke & Currie, 2007). Although on a much more primitive scale, the zebrafish brain still has
the same basic anatomical features as a human’s (forebrain, midbrain, and hindbrain) that
includes a peripheral and autonomic nervous system (Lieschke & Currie, 2007). Memory,
conditioned learning, and social behaviors are a few “higher-level” behaviors zebrafish have the
ability to exhibit (Lieschke & Currie, 2007). Due to ease of manipulation and human similarities,
zebrafish are often successfully used for toxicology studies in which the fish are exposed to a
chemical at early life stages and the resulting phenotypes influenced by these treatments will
emerge, making them an ideal candidate for this project.
The Escape Response
Vertebrates all possess basic behavioral responses to stimuli. In order for an animal to complete
an appropriate behavior response, the underlying neural systems must be properly developed.
The escape or startle response is an inherent survival behavior that allows an animal to remove
itself from a dangerous situation by a reflex response (Dominici & Blake, 1997). This response
is most often referred to as the “flight or fight" response in humans. The escape response in the
zebrafish is governed by a meticulously studied neural system and is commonly referred to as
the c-start. Two developmental milestones occur related to the startle response following the
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initial contractions. The behavior begins with spontaneous muscle contractions at 17 hours post
fertilization (hpf), and at 21 hpf a dechorionated fish will display a coil c-bend response when
touched (Drapeau et al., 2002). The coil displayed at this time point is an entire body contraction
that results in the tip of the tail touching the head generally in the direction away from an evoked
stimulus (Kalueff et al., 2013). At 48 hpf, the swimming of the fish has matured (Drapeau et al.,
2002) and c-bend response will be paired with a swim away from the stimulus. The ideal
response would be a smooth, effortless bend away from the stimulus and immediately
swimming away. In fish with dystonia and hyperactivity, the startle responses are uneven and
the fish will often get stuck in the c-bend and is unable to swim away. This spastic behavior to a
stimulus is referred to as “hitching” and in some of these cases the fish is not able to unbend
(Ganser, Yan, James, Kozol, & Topf, 2013).
The mauther neurons are large bilateral cells in the fish that receive external environmental
cues via hair cells along the lateral line (Reed & Jennings, 2010). These neurons are developed
by 17 hpf (Drapeau et al., 2002) and play a pivotal role in proper locomotion for the embryonic
zebrafish. When the fish is faced with an external stimulus, the mauthner cells will emit a
response using the excitatory and inhibitory interneurons in order to enable muscle contractions
to bend and swim away in the opposite direction of the stimulus (Figure 1). These neural signals
should communicate a contraction of lateral muscles on the side of the fish that is opposite to
the stimulus and a relaxing of the lateral musculature closest to the stimulus with the use of the
inhibitory neurons (Ganser & Dallman, 2009). During development, proper function of the
excitatory and inhibitory interneurons that synapse from the mauthner neurons onto motor
neurons play a critical role in the coordination of muscle excitation and inhibition that results in a
smooth bend and swim away response (Ganser & Dallman, 2009). Improper connections
present in any portion of this neurological circuit will disrupt the stereotyped smooth bend and
swim away escape behaviors of the larvae that are crucial to survival and will result in the
inability to escape predation in a real-life setting (Ganser & Dallman, 2009). A stereotyped
escape response will be indicative of normal neurological development of the embryos. These
behavioral data will serve as our gateway to looking at the neurodevelopmental and
neuroanatomical circuit anomalies underlying behavioral deficits in amphetamine exposed
embryos.
The purpose of this study is to learn more about how amphetamines influence early developing
nervous systems and the resulting survival behaviors those systems are responsible for
controlling, as well as potential phenotypic alterations caused by amphetamine exposure. We
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hope to contribute to the small portion of existing data on this subject and provide more
knowledge on the drugs that children are frequently exposed to at an early age using an
extensively studied animal model.
Materials and Methods:
Amphetamine Water Analysis
A preliminary study was implemented on the treatments to ensure that the amphetamine
treatment would not alter the water quality prior to initial fish trials. Four petri dishes were set up
with each treatment (10 μg/ml, 20 μg/ml, and 30 μg/ml amphetamine) including a control of 10
ml system water. Water parameters (pH, chlorine, nitrate, nitrite, alkalinity, and total hardness)
were recorded using Tetra 6-in-1 EasyStrips (lot # 5092, exp. 03.2017) at 0, 24, and 48-hour
time points.
Husbandry
All studies were conducted in accordance with the guidelines of the Institutional Animal Care
and Use Committee. Wild-type zebrafish purchased from local pet stores were housed in a flowthrough, filtered aquatic system recirculating pre-made water consisting of de-ionized water with
added salts with a 12 hour light – 12 hour dark cycle. 4 to 6 same-sex fish were housed together
in individual three-gallon aquariums until breeding. Water parameters (pH, ammonia,
temperature, hardness, nitrate/nitrite, and chlorine) were maintained at recommended amounts
(Reed & Jennings, 2010). Adults were fed flakes of standard fish food twice daily with an every
other day additional protein supplementation of live Artemia injected into the environment.
Egg Collection
12 hours prior to breeding, males and females at a ratio of 2:1 were placed in a perforatedbottom breeding tank with a mesh divider to separate the sexes. The divider was removed the
following morning simultaneous to turning on the overhead fluorescent lights to encourage egg
laying (Reed & Jennings, 2010). Following fertilization, fish were transferred to a different tank
and eggs were removed via transfer pipette from the bottom of the breeding tank less than 1
hour after the divider was removed. Embryos were exposed to treatment at the single cell phase
(one to two hours post fertilization) in order to achieve ideal developmental results and early
exposure.
Treatments
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The treatment groups were as follows: Control, 10 μg/ml amphetamine (obtained from licensed
GA pharmacy) and 20 μg/ml amphetamine, and 30 μg/ml amphetamine. Non- lethal
concentrations of amphetamine were obtained from a suggested amount in study focused on
zebrafish and drug abuse (Ninkovic & Bally Cuif, 2005). Amphetamine was mixed into 10 ml
system water in the petri dishes and embryos were placed directly into treatments for 24 hours
(Figure 2). To prevent dilution of treatments, eggs were first placed in 1 ml eppendorf tubes
using a transfer pipette and any residual water was removed from the surface prior to placing in
petri dishes. 20 eggs from entire clutch of multiple female and male matings were randomly
selected for each treatment group. At the 24 - hour time point, the embryos were removed from
treatment to be dechorionated. Dechorionation is the manual removal of a thin membrane called
the chorion surrounding the embryo and is required to clearly see the embryo’s movement and
internal structures following treatments. Dechorionation was performed under a dissecting
scope with fine tipped forceps. After dechorionating, fresh amphetamine solutions were
prepared and embryos were placed into individual wells of a 48-well plate with 500 μl fresh
treatment for another 24 - hour treatment time, resulting in 48 hours of total treatment. Petri
dishes and plates with embryos were kept in a 28.0 °C incubator for the entire treatment period.
Any dead embryos were removed from the dishes immediately to avoid possible contamination
to the remaining fish. After 48 hpf, 5-10 embryos from each group were sacrificed and
embedding for antibody staining.
Behavioral Analysis
For capturing startle responses, fish were individually placed into an arena (10 milliliters of 28°
C system water in a petri dish) under a Zeiss v12 AxioScope dissecting microscope and gently
touched by a thin dental pick in the mid-dorsal region after a 30 second acclimation time. The
touched-evoked escape assay was recorded using a Fastec Imaging HiSpec 1L 2G mono highspeed camera at a rate of 500 frames per second at both the 24 and 48 hpf time points for each
fish (Figure 2). The illumination under the petri dishes remained the same for the entirety of the
documentation. Duration of the recordings lasted from before the touch of the stimulus until a
completion of escape behavior and the tail was back to a relaxed state. We expected to see the
normal c-bend response away from the stimulus at 24 hpf and a c-bend swim away response
paired with a smooth swim away at 48 hpf with our control groups. Time it takes to achieve a full
coil for each fish in all treatment groups was documented in milliseconds by looking at individual
frames. The time to coil variable was analyzed using a two-way analysis of variance (ANOVA) in
MINITAB express software to look for existence of differences among treatment groups with an
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α = 0.05. In order to pinpoint where variables were significantly different, a Tukey’s HSD posthoc comparison was then used to further explore where significant interactions occurred within
treatments and across time with an α = 0.05.
Abnormal responses to an external stimuli will tell us that a disruption occurred developmentally
and will be considered a spastic response. A spastic response refers to any escape response
that deviates from the stereotyped reaction and can include hitching, hesitation, bending
towards the stimulus, corkscrew, and inability to complete a swim away or c-bend. Chi-square
tests were administered via MINITAB software to look for significant differences between
treatment groups with an α = 0.05 and a 95% confidence interval. Morphological abnormalities
(spinal curvature, abnormal/underdevelopment, tail malformations, etc.) for each treatment
group were also recorded and photographed.
Natural Chorion Emergence
To examine delays in early development, a common developmental toxicity experiment to
observe hatching from the chorion was implemented (Bourrachot, Simon, & Gilbin, 2008).
Zebrafish embryos were treated with the same amphetamine concentrations as mentioned
above (10 μg/ml, 20 μg/ml, and 30 μg/ml) and were observed for their natural chorion
emergence time, which occurs at 48 hpf (Fraysse, Mons, & Garric, 2006). The fish were placed
into petri dishes with respective treatments within one hour of fertilization and stored in an
incubator at 28° C. A 50% treatment change was implemented at 24 hpf. We chose a 50%
treatment change instead of 100% due to the fragility of the surrounding chorion at this time.
With preliminary trials, we saw that major disturbance to the environmental water in the form of
a 100% treatment change would encourage early hatching. Half of the treatment was carefully
removed from the top of the eggs in the dish and the new treatment was slowly pipetted down
the outer edge of the dish and gently swirled to incorporate new treatment. The different times
points used for observation were 24 (for mortality), 48, 54, 72, 78, 96, and 102 hpf and the
proportion of embryos emerged was counted for each time point and treatment group.
Complete hatching was considered to have occurred when the entire embryo was free of the
chorion (head and tail). Deceased embryos were removed from dishes to prevent potential
infection to other embryos. The average hatching time was analyzed using a one-way analysis
of variance (ANOVA) in MINITAB express software to look for existence of differences among
treatment groups with an α = 0.05. A Tukey’s HSD post-hoc comparison was then used to
further explore where significant interactions occurred with an α = 0.05.
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Survivorship
A greater amount of embryo manipulation, including dechorionation, was required during the
behavior trials, which occasionally resulted in death. Therefore, mortality was recorded for only
the natural emergence groups at 24 hpf. There were a total of 5 trials of 20 embryos per
treatment group that were documented for mortality, resulting in n = 100 sample size for each
treatment. Chi-square tests were administered via MINITAB software to look for significant
differences between treatment groups with an α = 0.05.

Body Length
Fish were treated with previously mentioned treatments within one hour of fertilization and
placed in an incubator at 28° C. A 100 % treatment change occurred at 24 hpf only. Total length
was measured for zebrafish in each treatment group at 48, 72, and 96 hpf. 20 fish per trial were
grouped together in petri dishes within respective treatments and photographed under the
Axiodissecting scope using a Zeiss camera. Fish were briefly chilled at 4° C for 5 minutes to
slow movement and reduce handling for photographs. A 2 micrometer measuring slide was
included in each photograph as a reference point. Pictures were then exported to the Tracker
version 4.90 (c) software for measurements. The calibration tape/stick function available with
Tracker software was used to obtain lengths of individual fish with minimal manipulation (Figure
10). Body length data was analyzed using a two-way ANOVA in MINITAB express software to
look for existence of differences among treatment groups over time with an α = 0.05. A Tukey’s
HSD post-hoc analysis was then used to further explore where significant interactions occurred
within treatments and across time.
Spinal Cord Assay
Fish from each treatment group were sacrificed following 48 hpf escape behavior analysis and
freshly embedded in OCT medium using a cube foil mold. After orienting 6 to 10 fish per
treatment per mold in the OCT, the fish were then snap-frozen in liquid nitrogen. Frozen molds
were used to thinly slice fish (12 μm) fish using a cryostat. Sections were obtained from the
approximate center of each fish to ensure cross-section of the spinal cord. Two cryosections
(with 6-10 cross sections each) were placed on positively charged slides and then fixed for ten
minutes using 4 % paraformaldehyde.
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The fish cross sections were then double-stained using an immunohistochemistry procedure
previously optimized to show expression of excitatory and inhibitory neurons within the spinal
cord of the cross sections (Ganser et. al., 2013). As previously discussed, a proper circuit
balance between the excitatory and inhibitory neurons must be appropriately developed within
the fish in order for the movements of the startle response to occur. For the inhibitory
expression, the glycine receptor antibody, mAb2b (synaptic systems, lot # 146111/11) was used
and stained green (488). Glyncinergic events are considered essential for a proper escape
response in a developing zebrafish and glycine is present before glutamate expression in the
spinal cord (Drapeau et. al, 2002). For the excitatory expression, the glutamate receptor
antibody, anti-NMDAR2A (synaptic systems, lot # 2709141), was stained red (555). A
glutamate-specific antibody was chosen to represent excitatory expression because glutamate
is considered the prominent excitatory neurotransmitter responsible for neural activity in the
locomotor region within the developing zebrafish after the 21 hpf time point (Declan, Buss, &
Drapeau, 2000, Drapeau et. al., 2000).
Completed slides were observed using a Zeiss LSM 700 laser scanning confocal microscope. 3
– 4 repeated trials were used for each treatment with 6-10 cross-sections per slide. Pictures
were captured of each cross section using identical settings (exposure, gain, etc.) with a z-stack
of each cross-section. Average expression was in the form of fluorescence arbitrary units (F. A.
U.) for both glutaminergic (555 channel) and glycinergic (488 channel) stains and were scored
by manually circling the region of interest (spinal cord) on each cross section with the Zen Blue
software imaging analysis tool. A negative control stain was prepared with the absence of the
primary antibodies and also analyzed and subtracted from final treatment values to account for
background signal.
Mean antibody values are expressed in fluorescent arbitrary units (F.A.U.). DAPI expression
values were obtained and used as average intensity values to control for consistent expressions
throughout. A negative control stain with secondary antibodies only was used for subtracting
background fluorescence signal for both glycine and glutamate specific antibodies. Expression
data was analyzed using a one-way ANOVA in MINITAB express software for each antibody to
look for existence of differences among treatment groups at each time point with an α = 0.05.

Results
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Amphetamine Water Analysis
It was found that the amphetamine treatments did not alter the water parameters at any time
point in any treatment group. pH remained at 6.8, chlorine content was 0 ppm (mg/L), nitrate
was 40 ppm (mg/L), nitrite was 0 ppm (mg/L), total alkalinity (KH) was 0 ppm, and total
hardness (GH) was 150 ppm for all amphetamine groups and control group for 0, 24 and 48
hour time points.
Escape Behavior
For the behavior study, we examined the time to coil variable along with spastic vs. normal
escape response. The ANOVA revealed a significant treatment by time interaction with a value
of p < 0.0001 (Table 1, Figure 3). A steep increase in escape response times occurred between
the 24 hpf and 48 hpf time points, with an average of most likely due to the rapid development
of locomotive circuits during this time. Our Tukey’s HSD (honest significant difference) post-hoc
analysis shows a statistical difference in the time it takes for the control fish to complete a cbend away from a stimulus compared to all amphetamine treatment fish with the 10 μg/ml, 20
μg/ml, and 30 μg/ml concentrations at both 24 and 48 hpf (p < 0.05 for all comparisons between
control fish and each of the treatments). At 24 hpf, the fish had escape response times of 184.5
ms ± 27.46 (mean ± SE) for control, 443.16 ms ± 31.81 with 10 μg/ml, 329.46 ms ± 35.40 with
20 μg/ml dose group, and 401.56 ms ± 36.77 for the 30 μg/ml group. At 48 hpf, the fish had
much faster responses, with times of 15.93 ms ± 0.72 for control, 22.08 ms ± 1.38 with 10
μg/ml, 20.8 ms ± 0.56 with 20 μg/ml dose group, and 22.5 ms ± 1.90 for the 30 μg/ml group. A
significant difference was not found when comparing the amphetamine treatments.
Corkscrew vs. Normal
The corkscrew behavior was only observed at 24 hpf with this experiment. The control fish
displayed a 20.5% spastic, 79.5% normal response rate while the amphetamine fish showed a
much higher spastic behavior rate at 47.2% spastic, 52.8% normal for 10 μg/ml, 43.8% spastic,
56.3% normal for 20 μg/ml, and 45.2% spastic, 54.9% normal for 30 μg/ml fish. There was a
significant difference found between spastic escape responses and all amphetamine
treatments, with a p < 0.05 for each control to amphetamine dose comparison (Table 2).
Interestingly, a similar biphasic trend (to the escape response) was also observed with the
amphetamine fish for the spastic behaviors where more spastic behaviors were seen with low
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(10 μg/ml) and high (30 μg/ml) amphetamine dose compared to the mid-range (20 μg/ml) dose
although differences were not statistically significant.
Natural Emergence:
The control fish emerged from their chorions earlier than the 10 μg/ml, 20 μg/ml, and 30 μg/ml
amphetamine fish. The average hatching time for control embryos was control group (mean ±
SE) = 49.2 hpf ± 0.98, 10 μg/ml = 61 hpf ± 1.30, 20 μg/ml = 57.8 hpf ± 1.18, and 30 μg/ml = 58.8
hpf ± 1.08 for amphetamine fish (Table 3, Figure 6). All amphetamine treated fish hatched
significantly later than controls with p < 0.0001 for each group (Table 3). A significance
difference was not found when comparing the amphetamine treated groups.
Survivorship
The control fish had a mortality rate of 12 at 24 hpf compared to the amphetamine fish which
had a 21 for 10 μg/ml, 19 for 20 μg/ml, and 22 for 30 μg/ml treatments (Figure 8). Although
numerical differences were documented, there were no statistical differences when comparing
amphetamine treated fish to controls (Table 4). All p values were above 0.05.
Morphology
A suite of morphological abnormalities was observed within all treatment groups of
amphetamine-exposed fish. These fish displayed various deformities including several with tail
malformation and tail underdevelopment, extreme spinal curvature (lordosis), and smaller or
exceedingly large yolk sacs (Figure 9). Other than this span of previously mentioned anomalies,
there was no amphetamine-exposed specific deformity documented.
Body Length Analysis
ANOVA indicated significant main effects of treatment (p = 0.000) and time (p = 0.000), but not
significant interactive effects of treatments*time (p = 0.704) (Table 5). The significant treatment
effect tells us that time is not a factor when looking at overall treatment effects (Figure 11). The
significant main effect of time indicates that each treatment group of fish are continuing to grow
in body length over the 3 time points (Figure 12). Standard error for the mean (mean ± SE)
average body lengths and ANOVA values are included in table 5. Overall, the low (10 μg/ml)
and high dose (30 μg/ml) amphetamine groups were significantly shorter in length (mm) than
the control fish (p = 0.000), with mean body lengths of (mean ± SE) 3.10 ± 0.04 for 10 μg/ml,
3.11 ± 0.04 for 30 μg/ml, and 3.30 ± 0.03 for the control group.
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When comparing between the amphetamine treatments, the low and high dose (10 μg/ml, 30
ug/ml) fish were both significantly shorter than the mid range dose (20 μg/ml) (p < 0.001)
(Figure 11). There were no statistical differences found between 10 μg/ml and 30 μg/ml doses,
and control and 20 μg/ml with treatment comparisons.
Spinal Cord Imaging
The highest amphetamine dose, 30 μg/ml, had the greatest mean mAb2b/glycine antibody
expression (mean ± SE) (12.21 F.A.U. ± 1.90 (mean ± SE) compared to the control group (4.67
F.A.U. ± 1.19) and the low (7.56 F.A.U. ± 2.38) and mid-range (5.02 F.A.U. ± 0.60)
amphetamine groups. The high amphetamine dose also had the greatest mean antiNMDAR2A/glutamate expression (5.93 F.A.U. ± 0.88) compared to the control group (2.83
F.A.U. ± 0.79) and the low (3.48 F.A.U. ± 0.67) and mid-range (4.46 F.A.U ± 1.76) amphetamine
groups (Figure 13). The ANOVA did not show a significant difference among treatment groups
with anti-NMDAR2A expression, however a significant difference was found with mAb2b (p =
0.0041) (Figure 13). A Tukey’s HSD post-hoc comparison was used in conjunction with the
ANOVA to look for statistical significance between the various treatment groups with an α =
0.05. With mAb2b, there was significantly more F.A.U expression in the high amphetamine dose
compared to the mid-range (p = 0.0085) and the control group (p = 0.0074) (Table 6).
Discussion
Currently, there are very few existing reports that examined the influence of amphetamines on
development and behavior in the zebrafish. A majority of the existing studies using
amphetamines and zebrafish focuses on drug addiction properties in terms of conditioned place
preference and acute administration in adult fish (Ninkovic & Bally- Cuif, 2005). Juvenile or adult
zebrafish are most commonly used for amphetamine studies, with the youngest used at 6 days
past fertilization (Irons, MacPhail, Hunter, & Padilla, 2010).
In the 2010 Irons study where early stage (6 days old) zebrafish were exposed to
amphetamines, researchers found that embryos displayed an “inverted-U” behavioral doseresponse pattern with locomotor activity in response to light and dark environments. This
biphasic, inverted-U behavior response has also been documented in rodent and other fish
studies when exposed to stimulants (cocaine and amphetamines) and ethanol (Irons et al.,
2010). The inverted-U indicates hypoactivity at low and high doses but hyperactivity with the
midline dosages. It is interesting to note that we found a similar biphasic pattern with every

15

aspect of this study (behavior, hatching, mortality, body length, and excitatory/inhibitory spinal
cord expression) although a statistical difference was not present between every amphetamine
dosage. We suspect the lack of significance between amphetamine groups, especially with
escape behavior, is most likely due to the high variation in response times. Furthermore,
damaging effects of amphetamine could also take longer to manifest than 1 – 3 days after
exposure. With larger sample sizes and extended testing time points, we predict that more
significant differences between amphetamine treatments would occur.
In terms of behavior and activity, it is well documented that amphetamines lower impulsivity,
reaction time, and motor activity in humans; however, the mechanisms behind this decreased
activity are unknown (Zahn, Rapoport, & Thompson, 1980). It is possible that the general
decrease in activity caused by amphetamine exposure could largely account for the slower
escape response times with our amphetamine treated fish. With our escape responses, we
found significant interaction with treatment, time, and treatment across time factors. It is
important to note that the fish were much faster to complete c-bends at the second time point
(48 hpf) compared to the first (24 hpf) with all treatment groups. We credit the increased speeds
to the rapid development during this timeframe.
Not only have we seen a diminished motor function with the slower reaction time with all
treatment groups in the amphetamine-treated fish, but also increased spastic behaviors in
response to a stimulus. The spastic responses were mostly in the form of a “corkscrew” where
the fish would go beyond the typical tail touch to head coil and wrap the tail around itself in a
spiral fashion. A similar corkscrew swimming behavior has previously been documented in
larval zebrafish exposed to caffeine, which is also a central nervous system stimulant, and is
considered a seizure phenotype (Wong et al., 2010). Previous work also suggests that
therapeutic stimulant use could lower the threshold for seizure occurrence in children (Hemmer,
Pasternak, Zecker, & Trommer, 2001), which could potentially be occurring with our stimulant
exposed zebrafish that exhibit spastic responses.
We also observed significantly shorter body lengths with all amphetamine treatments groups.
Although a significant interaction term was found with treatments, there was no significance
present with treatments across time, meaning that time had no bearing on the treatment effects
of amphetamine. These results are similar to previous human (Cernerud et. al., 1996) and
rodent experiments (Tan, 2003, Smith & Chen, 2010) that found early amphetamine exposure
decreases height. Conversely, more recent work found that mixed amphetamine salts have no
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effect on weight and height of children after 3 years of treatment (Pliszka, Matthews, Braslow, &
Watson, 2006). Our body length data clearly shows shorter body lengths with 3 doses of
amphetamine and early exposure, which helps clarify the conflicting existing research. In
addition, significant differences were found between low and high dose of amphetamine
compared to mid-range dose, which shows a strong biphastic dose response pattern,
supporting the theory of a compensatory mechanism occurring with a mid-range amphetamine
dose.
Along with shorter body lengths, various morphological deformities were also seen with
amphetamine treated fish in the form of lordosis, blunted/shorter tail, and enlarged yolk sac at
both 24 and 48 hpf. With the exception of lower body weights and heights and changes in
dendritic morphology (Berman et al., 2008), a lack of physical deformities has been previously
reported with amphetamine exposure in all species. We speculate that an increased amount of
deformities with our amphetamine exposed fish occurred because of early exposure during key
developmental time frames.
When using antibody staining to examine inhibitory and excitatory expression within the
interneural structures, we found that the mid-range amphetamine dose, 20 μg/ml, had the
lowest glycine expression, and the high-dose had a significantly higher glycine expression
compared to the mid-range amphetamine dose and control. Since glycine is an inhibitory
neurotransmitter within the central nervous system, the overexpression in the high
amphetamine dose explained the slower time to coil escape response times, if the increased
amount of interneural glycine is indeed causing reaction time deficits within this treatment group.
Additionally, the lower glycinergic expression found with the mid-range dose (20 μg/ml) is
consistent with their higher escape response times, suggesting an underlying compensatory
mechanism (neural plasticity, etc.). In human infants, defects in gylcinergic expression results in
a motor disorder called hyperekplexia, which is characterized by an exaggerated startle
response (Harvey et al., 2008). A similar behavioral phenomenon appears to be occurring in our
zebrafish embryos with amphetamine exposure.
We were surprised to find smaller differences among the treatment groups for the glutamate
(excitatory) expression. Since glutamate is considered the chief excitatory neurotransmitter
within the locomotor region of the embryonic and larval zebrafish (Declan et. al., 2000) and
stimulants, like amphetamine, increase excitatory activity, we predicted a larger difference in
expression between control and amphetamine treatments. Our data shows the highest
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averages for glutamate expression in the high-dose amphetamine treatments. A slight increase
in glutamate receptor measures (GluR1) was also observed with acutely amphetamine-exposed
rats in a 2009 study, however, the results were not significant (Nelson et al., 2009).
Amphetamines have been shown to alter morphology of neurons in rats and patterns of synaptic
activity within the nucleus accumbens (Robinson T. E. & Kolb B., 1997), however, the effects of
amphetamines on the locomotor mauthner neurons of the fish have never been examined. It is
possible that amphetamine exposure is altering the mauthner cell’s interneural morphology in
our fish, which would have behavior consequences. Overall, these synaptic signaling
overexpressions, especially within inhibitory values, appear to be altering the delicate balance
between excitatory and inhibitory expression and communication in the spinal cord and could
account for behavior delays and deficits in these embryos, suggesting that amphetamines
disrupt development of the nervous system and alter behaviors necessary for survival.
One limitation of this study is the inability to accurately measure amphetamine uptake of the
embryos. It is possible that the exposed embryos absorbed less than the intended dose of the
amphetamine due to the surrounding chorion layer, even though we know that exposure did
occur due to the large behavioral differences and phenotypic anomalies recorded when
compared to controls. In addition, due to the minuscule size and necessary aquatic
environment, it is difficult to obtain an accurate weight of a single freshly laid zebrafish egg.
Because of this, applying human-relevant dosages of amphetamine treatment to zebrafish
embryos is challenging. In the future, we would like to expand our dose range to examine
changes occurring at a higher and lower exposure.
There are also several novel aspects of this study. The escape response has been used as an
assay for developmental delays in environmental toxicity and pollutant experiments (Stehr,
Linbo, Incardona & Scholz, 2006)(McClain, Stapleton, Tilton, & Gallagher, 2012) but currently
has never been used in accordance with amphetamines. Additionally, natural chorion
emergence and excitatory/inhibitory spinal cord expression have also never been looked at with
amphetamines and zebrafish with this early of exposure. The large clutch size of zebrafish eggs
combined with petri dish and 48 - well plate treatments allows for a rapid through-put method of
assaying pharmaceuticals on zebrafish stereotyped behaviors that could open the door to more
research possibilities in the future. The present experiment using 24 and 48 hpf embryos offers
a new and unique perspective on early amphetamine exposure during peak developmental time
frames.
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Early life stages of any organism is a precarious time period due to multiple changes occurring
in a short amount of time. With the dramatic rise in ADHD diagnoses in children over the past
two decades and the resulting increase in amphetamine prescriptions, it is becoming
increasingly more important that we understanding the developmental implications with such an
early exposure. Overall, we saw a significant difference in escape response times and amount
of spastic responses, natural chorion emergence, body lengths, and glycine expression in the
amphetamine treated fish compared to controls for various time points with very early exposure.
This strongly indicates a developmental delay with amphetamine exposure in zebrafish
embryos. The developmental delays, along with the suite of morphological abnormalities
documented in this study, emphasizes the need for complementary studies. Most importantly,
thousands of children and adolescents ingest amphetamines daily but know little about how
these drugs influence the development of their neurological systems once they reach adulthood,
making additional research on development and early amphetamine exposure all the more
necessary.
Integration:
This project has successfully incorporated a spectrum of biological components to help answer
our research questions. Embryology, neuroscience, pharmacology, physiology, morphology,
and behavioral biology are the main fields that we applied to our research to gain a better
understanding of how amphetamines influence development during early life stages.
On an observational level, we examined early stereotyped fish behavior in response to an
environmental perturbation. Observing animal behavior is a common research method that is
not only used for testing environmental influences and pharmaceuticals, but is also frequently
utilized in ecological and environmental biology. Watching the inherent escape behavior allowed
us to gain a better understanding of the disruptions that occurred within internal anatomy of the
treated fish and how these disruptions were manifested. A behavioral change or delay caused
by an external influence found in a lower level species, such as the zebrafish, can be applied to
humans due to the previously mentioned similarities (embryonic development, basic nervous
system, behavior etc.) between the two organisms.
However, changes in behavior only tell us one part of the story. In order to further investigate
the effects of amphetamines on development and understand the behaviors observed, we
needed to understand how these pharmaceuticals were influencing neuronal development
internally. To do this, we took our research to a cellular level inside embryos and used common
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immunofluorescence antibody staining techniques to visualize growth of the individual neural
cells within the spinal cord of the zebrafish embryos responsible for these escape behaviors. In
addition, we used morphology to examine phenotypic anomalies caused by various treatments.
The combination of observing the entire organism along with the internal features provides a
multidimensional study. The benefit of integrating these organismal and cellular fields of biology
allows us to look at our research questions from different angles and has resulted a more
robust, multi-faceted project. We were able to not only observe the behaviors (escape and
hatching) and morphological differences (body lengths and deformities) influenced by
amphetamines but also provide support for the external differences with microscopy and
staining.
Tables and Figures
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Figure 1: Diagram illustrates the primary neural circuit in a zebrafish embryo responsible for the
c-bend startle response. Mechanoreceptor hair cells from the lateral line receive environmental
disturbance signals and transport those to the commissural spiral fiber neurons of the mauthner
cell, which then signal the surrounding muscles to respond accordingly.
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Figure 2: Behavior experimental set-up. Figure shows the zebrafish eggs environmentally
exposed to increasing dosages of amphetamine in 10 milliliter petri dishes. The escape
behaviors are then individually documented using high-speed videography at both 24 and 48
hpf time points.

22

500
450
400

Time (ms)

350
300
250
200

*

150
100
50
0
Control

10
20
Amphetamine Concentration (μg/ml)

30

30

25

Time (ms)

20

*
15

10

5

0
Control

10
20
Amphetamine Concentration (μg/ml)

30

Figure 3: Average time to coil (mean ± SE; milliseconds) for escape response. Top graph
represents time to coil at 24 hpf and lower graph represents time to coil at 48 hpf. Single
asterisks (*) represent statistical difference from amphetamine groups (α= .05). No statistical
differences were found between amphetamine treatment groups. Error bars reflect standard
error of the mean.
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Table 1: The table includes average time to coil (ms), standard error of the mean, and sample
sizes (n) for both 24 and 48 hpf. Two-way ANOVA values and Tukey’s post-hoc p-values for
comparing treatment groups are also included.

Figure 4: Normal vs. corkscrew response. Photograph on the left displays a stereotypical cbend escape response at 24 hpf. The right side photograph shows an abnormal corkscrew
behavior in response to a stimulus.
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Figure 5: Frequency of Spastic (corkscrew) vs. Normal Escape Behavior in Response to
Amphetamine Exposure. Charts represent percent spastic vs. normal escape response
individuals at 24 hpf for each treatment group.

Table 2: Standard error of the mean, sample sizes (n), and Chi-square values are given for
each comparison. Control fish displayed significantly more spastic responses compared to
amphetamine fish.
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Figure 6: Average hatching time. Figure shows the average hatching time (in hours post
fertilization) for all amphetamine and control treatment groups. Single asterisks (*) represent
statistical difference from amphetamine groups (α= .05). No statistical differences were found
between amphetamine treatment groups. Error bars reflect standard error of the mean.

Table 3: Table shows mean hatching time (hpf) for each treatment group. Standard error of the
mean, sample sizes (n), and Tukey’s HSD post-hoc comparison p values are given. A
significant interaction term was found with the one-way ANOVA for average hatching time.
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Figure 7: Natural Chorion Emergence. The chart shows the time points and number of
individuals hatched for each treatment group at the various observed time points (24, 48, 54, 72,
and 78 hpf).
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Figure 8: Survivorship. Figure shows the percent of embryo death for each treatment group at
24 hpf. n = 100 for each treatment. No statistical differences were noted between treatment
groups.

Table 4: Table show the number of deceased fish at 24 hpf for each treatment group. The chisquare values are given to compare each treatment group. Significant differences were not
found between any of the treatment groups.
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Figure 9: Morphological anomalies. Pictures show various phenotypic deformities documented
with each amphetamine treatment dose at both 24 (top) and 48 (bottom) hpf. These deformities
include lordosis, enlarged yolk sac, and underdeveloped or complete lack of tails.
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Figure 10: Tracker Version 4.90 (c) Software. Picture shows the tracker software used for
obtaining body lengths of embryos. Blue 2 mm line with plus signs is the calibration tape and the
blue line on top of embryo with arrows is the measuring tape function.
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Figure 11: Average Body Length (mean ± SE; millimeters). Graph shows the average (mean)
body length for zebrafish (48, 72, and 96 hpf time points combined). Bars with same letter (A or
B) are not statistically different (α= .05). Error bars reflect standard error of the mean.
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Figure 12: Average Body Length over Time (mean ± SE; millimeters).. The chart shows the
cumulative average (mean) body lengths (mm) for fish of all treatments within each time point. A
significant interaction term (p = 0.000) was found for the time variable in the body length study
using a two-way ANOVA, meaning that the fish of all treatment groups grew at each time point.
Error bars represent the standard error of the mean.

Table 5: Table shows mean body length (mm) with standard error of the mean and sample size
(n). Two-way ANOVA values for each comparison factor and Tukey’s post-hoc p-values for
comparing treatment groups are also included.
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Figure 13: Inhibitory/excitatory spinal cord expression (mean ± SE; F. A. U.). F. A. U.
expression within the spinal cord of 48 hpf freshly embedded fish for each treatment group. A
negative control average F.A.U. expression has been included to account for background
signal. Error bars reflect standard error of the mean. Top: the glycine specific antibody, mAb2b
(inhibitory) expression. Single asterisks (*) represent statistical difference from control (α= .05).
Double asterisks (**) represent statistical difference from 30 μg/ml amphetamine treatment.
Bottom: the glutamate specific antibody, anti-NMDAR2A (excitatory) expression. No statistical
differences present.
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Figure 14: Inhibitory/excitatory spinal cord expression. The glycine specific antibody, mAb2b
(inhibitory), and glutamate specific antibody, anti-NMDAR2A (excitatory), expression within the
spinal cord of 48 hpf freshly embedded fish for each treatment group. Pictures are maximum
intensity images and were taken using confocal microscopy with 40X magnification.
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Table 6: The table shows the F. A. U. expression averages (mean) for glycine-specific antibody,
mAb2b, and glutamate-specific antibody, anti-NMDAR2A as well as ANOVA values for each
antibody and Tukey’s post-hoc p-values for comparing treatment groups.
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